Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital-Reference-Cited by-同舟云学术

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital

Published:2018-09-25 Issue:12 Volume:25 Page:998-1004
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Patel Devin N¹,Jha Shalini²³,Howard Lauren E²³,Amling Christopher L⁴,Aronson William J⁵⁶,Cooperberg Matthew R⁷,Kane Christopher J⁸,Terris Martha K⁹¹⁰,Chapin Brian F¹¹,Freedland Stephen J¹³

Affiliation:

1. Division of Urology; Department of Surgery; Samuel Oschin Comprehensive Cancer Institute; Cedars-Sinai Medical Center; Los Angeles California USA

2. Department of Biostatistics and Bioinformatics; Duke University School of Medicine; Durham North Carolina USA

3. Division of Urology; Veterans Affairs Medical Center; Durham North Carolina USA

4. Division of Urology; Department of Urology; Oregon Health and Science University; Portland Oregon USA

5. Department of Urology; Los Angeles School of Medicine; University of California; Los Angeles California USA

6. Urology Section; Department of Surgery; Veterans Affairs Greater Los Angeles; Los Angeles California USA

7. Department of Urology; UCSF Helen Diller Family Comprehensive Cancer Center; San Francisco California USA

8. Urology Department; University of California San Diego Health System; San Diego California USA

9. Section of Urology; Veterans Affairs Medical Center; Augusta Georgia USA

10. Section of Urology; Medical College of Georgia; Augusta University; Augusta Georgia USA

11. Department of Urology; Division of Surgery; The University of Texas MD Anderson Cancer Center; Houston Texas USA

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.13806/fullpdf

Reference27 articles.

1. Concept and viability of androgen annihilation for advanced prostate cancer;Mohler;Cancer,2014

2. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial;Kyriakopoulos;J. Clin. Oncol.,2018

3. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N. Engl. J. Med.,2017

4. Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives;Bayne;Eur. Urol.,2016

5. Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation;Swanson;J. Urol.,2004

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A commentary on “assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer - an in-depth quantitative evaluation and retrospective cohort analysis”;International Journal of Surgery;2024-04-09

2. Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer - an in-depth quantitative evaluation and retrospective cohort analysis;International Journal of Surgery;2024-03-18

3. Practice Patterns and Patient Experience of Care Among US Veterans with Prostate Cancer: A 10-Year Scoping Review;JU Open Plus;2024-01

4. The impact of race on survival in metastatic prostate cancer: a systematic literature review;Prostate Cancer and Prostatic Diseases;2023-08-17

5. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial;European Urology;2023-06